

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
08 May 2025 (08.05.2025)



(10) International Publication Number
WO 2025/093824 A1

(51) International Patent Classification:

A61K 35/761 (2015.01) *A61P 35/00* (2006.01)
A61K 31/337 (2006.01) *C12N 15/86* (2006.01)
A61K 39/395 (2006.01) *A61K 39/00* (2006.01)
A61K 45/06 (2006.01)

DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/FI2024/050592

Published:

— with international search report (Art. 21(3))

(22) International Filing Date:

04 November 2024 (04.11.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

20236227 02 November 2023 (02.11.2023) FI

(71) Applicant: **TILT BIOTHERAPEUTICS OY** [FI/FI]; c/o
Biomedicum 2B, Tukholmankatu 8 B, 00290 Helsinki (FI).

(72) Inventors: **JIROVEC, Elise**; c/o TILT Biotherapeutics Oy,
c/o Biomedicum 2B, Tukholmankatu 8 B, 00290 Helsinki
(FI). **QUIXABEIRA, Dafne**; c/o TILT Biotherapeutics Oy,
c/o Biomedicum 2B, Tukholmankatu 8 B, 00290 Helsinki
(FI). **HEMMINKI, Akseli**; c/o TILT Biotherapeutics Oy,
c/o Biomedicum 2B, Tukholmankatu 8 B, 00290 Helsinki
(FI). **SANTOS, João Manuel**; c/o TILT Biotherapeu-
tics Oy, c/o Biomedicum 2B, Tukholmankatu 8 B, 00290
Helsinki (FI).

(74) Agent: **LAINE IP OY**; Porkkalankatu 24, 00180 Helsinki
(FI).

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,

(54) Title: ONCOLYTIC ADENOVIRUS, IMMUNE CHECKPOINT INHIBITOR AND CHEMOTHERAPEUTIC AGENT COMBI-
NATION THERAPY OF CANCER

(57) Abstract: The present invention relates to combination therapy with oncolytic viruses, particularly oncolytic adenoviruses, check-
point inhibitors and chemotherapeutic agents, such as paclitaxel, for the treatment of cancer, particularly to a combination comprising
(a) an oncolytic adenoviral vector encoding CD40L as a transgene and (b) one or more immune checkpoint inhibitors for use in com-
bination with (c) a chemotherapeutic treatment in the treatment of cancer.

WO 2025/093824 A1